Abstract
While remarkable advances have been made in the treatment of pediatric leukemia over the past decades, new therapies are needed for children with advanced solid tumors and high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study.
Document Type
Article
Publication Date
4-12-2017
Digital Object Identifier (DOI)
https://doi.org/10.2147/OTT.S124008
Repository Citation
Wagner, Lars M. and Adams, Val R., "Targeting the PD-1 Pathway in Pediatric Solid Tumors and Brain Tumors" (2017). Pediatrics Faculty Publications. 227.
https://uknowledge.uky.edu/pediatrics_facpub/227
Notes/Citation Information
Published in OncoTargets and Therapy, v. 10, p. 2097-2106.
© 2017 Wagner and Adams.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.